XTNT (Xtant Medical Holdings) ROE % Adjusted to Book Value : -21.61% (As of Sep. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Xtant Medical Holdings ROE % Adjusted to Book Value?

Xtant Medical Holdings's ROE % for the quarter that ended in Sep. 2024 was -44.30%. Xtant Medical Holdings's PB Ratio for the quarter that ended in Sep. 2024 was 2.05. Xtant Medical Holdings's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -21.61%.

Xtant Medical Holdings ROE % Adjusted to Book Value Historical Data

The historical data trend for Xtant Medical Holdings's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xtant Medical Holdings ROE % Adjusted to Book Value Chart

Xtant Medical Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-13.52

-12.42

0.54

Xtant Medical Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															33.04	-11.31	-11.11	-18.21	-21.61

Competitive Comparison of Xtant Medical Holdings's ROE % Adjusted to Book Value

For the Medical Devices subindustry, Xtant Medical Holdings's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xtant Medical Holdings's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xtant Medical Holdings's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Xtant Medical Holdings's ROE % Adjusted to Book Value falls into.

Xtant Medical Holdings ROE % Adjusted to Book Value Calculation

Xtant Medical Holdings's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	1.54%	/	2.87
	=	0.54%

Xtant Medical Holdings's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-44.30%	/	2.05
	=	-21.61%

Xtant Medical Holdings ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Xtant Medical Holdings's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Xtant Medical Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xtant Medical Holdings Inc (AMEX:XTNT) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

XMS:Germany

Address

664 Cruiser Lane, Belgrade, MT, USA, 59714

Website

http://www.xtantmedical.com

Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.

Executives

Kevin D Brandt	officer: VP & Chief Commercial Officer	11621 RESEARCH CIRCLE, ALACHUA FL 32615
Lori D Mitchell-keller	director	664 CRUISER LANE, BELGRADE MT 59714
Jonn R. Beeson	director	664 CRUISER LANE, BELGRADE MT 59714
Scott C Neils	officer: Interim CFO	664 CRUISER LANE, BELGRADE MT 59714
Mark A. Schallenberger	officer: Chief Operations Officer	664 CRUISER LANE, BELGRADE MT 59714
Sean E Browne	officer: President and CEO	664 CRUISER LANE, BELGRADE MT 59714
Stavros G. Vizirgianakis	director	1/16-18 TENNYSON ST., WILLIAMSTOWN NORTH, VICTORIA CA 3016
Orbimed Rof Ii Llc	director, 10 percent owner	601 LEXINGTON AVE., 54TH FLOOR, NEW YORK NY 10022
Greg Jensen	officer: VP, Finance and Interim CFO	664 CRUISER LANE, BELGRADE MT 59714
Ronald G. Berlin	officer: VP & Chief Operations Officer	664 CRUISER LANE, BELGRADE MT 59714
Kathie J. Lenzen	officer: SVP Fiance & Admin. & CFO	664 CRUISER LANE, BELGRADE MT 59714
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Matthew Rizzo	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Michael Eggenberg	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Robert Mcnamara	director	C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750